Date post: | 28-Dec-2015 |
Category: |
Documents |
Upload: | osborn-russell |
View: | 216 times |
Download: | 2 times |
Meeting goals
• Provide participants – Current status regarding• Classification• Diagnosis• Management
– Update on the latest developments in neuroendocrine tumors (NETs)
• Address key open questions & controversies in the management of NETs
• Present characteristic clinical cases
ENETS GUIDELINESLatest 2015 updated
ENETS Consensus
Naming Consistency Tissue of origin
Diagnosing Nature of disease WHO classification
Grading Biological behavior Proliferative fraction *
Staging Disease extension TNM staging
TNM classification
TNM classification
Targeting NETs – Data from Phase III studies
• Somatostatin receptors highly expressed by NETs
– Targeting SSTRs can provide besides symptom also disease control
• New potential targets :– mTOR, PI3K, VEGF inhibitors– Other antiangiogenic agents
• Targeted & combination treatments evolving
Long acting - somatostatin analogs
Sunitinib
Everolimus Bevacizumab
Multidisciplinary team achievements
• Improved 5 year survival– UK colorectal & esophageal cancer
• Improved 2 year survival– UK neck & head cancer
• Improved 7 year relative survival– Sweden breast cancer
Gastroenterologists
Geneticists
Endocrinologists
Surgeons
Research nurses
Oncologists
Radiologists –Nuclear Medicine
Pathologists
Target audience – Multidisciplinary team (MDT)
NET patient
Advances of MDT management of NETs
• Accurate diagnosis and staging• Evaluation of performance status and quality of
life• Consensus regarding patient’s care plan• Cohesive delivery of support, therapy and
information on prognosis• Continous reassesment, discussion, and peer
review of individualized care plan